6-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine → HCID 53378265, compound
Reaction equation
Cl[C:2]1[N:3]=[C:4]([N:23]2[CH2:28][CH2:27][O:26][CH2:25][CH2:24]2)[C:5]2[N:11]=[C:10]([CH2:12][N:13]3[CH2:18][CH2:17][CH:16]([C:19]([OH:22])([CH3:21])[CH3:20])[CH2:15][CH2:14]3)[CH:9]=[CH:8][C:6]=2[N:7]=1.[CH3:29][C:30]1[N:35]=[C:34]([NH2:36])[CH:33]=[CH:32][C:31]=1B1OC(C)(C)C(C)(C)O1>>[NH2:36][C:34]1[N:35]=[C:30]([CH3:29])[C:31]([C:2]2[N:3]=[C:4]([N:23]3[CH2:28][CH2:27][O:26][CH2:25][CH2:24]3)[C:5]3[N:11]=[C:10]([CH2:12][N:13]4[CH2:18][CH2:17][CH:16]([C:19]([OH:22])([CH3:21])[CH3:20])[CH2:15][CH2:14]4)[CH:9]=[CH:8][C:6]=3[N:7]=2)=[CH:32][CH:33]=1Participants
3
Procedure
2-(1-((2-Chloro-4-morpholinopyrido[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-ol from Example 8 (70 mg) was reacted with 6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine via General Procedure A to produce 32.1 mg of 116 following reverse phase HPLC purification. MS (Q1) 478.3 (M)+
Workup
- customto produce
- custom32.1 mg of 116 following reverse phase HPLC purification
Sources & evidence
- ORD record
- ord-33c8a3ed15854fd68578378b58ba88db
- Source dataset
- uspto-grants-2013_05
- Patent number
- US08440651B2
Reaction notes
Loading…